Clinical Trial Update: Gene Therapy for ACM Due to a PKP2 Pathogenic Variant [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 gene therapy trial for arrhythmogenic cardiomyopathy caused by PKP2 pathogenic variants is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmogenic Cardiomyopathy
• Arrhythmogenic Right Ventricular Cardiomyopathy

Drugs mentioned

• Lexeo PKP2 gene therapy

Snippet

Sponsor: Lexeo Therapeutics | Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING